Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration

Figures & data

Table 1 Overview of published data

Reference	^Citation46	^Citation47	^Citation33	^Citation35	Together
Authors	Richard^a	Barthelmes	Eleftheriadou	Traine
Year of publication	2015	2018	2018	2019	2015–19
Study design	P	R	R	R
n (eyes)	511	212	148	231	1,102
Patient retention over 24 months (%)	84.0	64.2	83.8	80.0	78.0
VA gain (12 months)^b	9.8	n.r.	5.9	5.7	7.1
VA gain (24 months)^b	9.5	6.0	6.4	5.7	6.9
Injections in year 1 (n)	7.5	7.0	7.2	7.7	7.4
Injections in year 2 (n)	3.0	5.8	4.6	4.4	4.5
Disease stability by end of year 2 (%)	50.1	92.0	57.3	52.0	62.9
Treatment intervals ≥12-weeks in year 2 (%)	48.3	24.0	52.8	46.9	43.0

Notes: ^aThe VIEW 1 and 2 studies used a “capped PRN” approach for the 2q8 group: bimonthly Aflibercept injection after the loading phase in year one; patients that had achieved disease stability by then proceeded under a mandatory proactive treatment every 12 weeks as long as no disease activity was detected^{9 b}ETDRS letters.

Abbreviations: P, prospective; R, retrospective real-life, n.r., not reported.

Regillo CD, Busbee BG, Ho AC, Ding B, Haskova Z. Baseline predictors of 12-month treatment response to ranibizumab in patients with wet age-related macular degeneration. Am J Ophthalmol. 2015;160(5):1014–1023.e2. doi:10.1016/j.ajo.2015.07.034

 Web of Science ®Google Scholar

Finger RP, Wickremasinghe SS, Baird PN, Guymer RH. Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration. Surv Ophthalmol. 2014;59:1–18. doi:10.1016/j.survophthal.2013.03.009

 PubMed Web of Science ®Google Scholar

Eleftheriadou M, Gemenetzi M, Lukic M, et al. Three-year outcomes of aflibercept treatment for neovascular age-related macular degeneration: evidence from a clinical setting. Ophthalmol Ther. 2018;7:361–368. doi:10.1007/s40123-018-0139-5

 PubMed Web of Science ®Google Scholar

Traine PG, Pfister IB, Zandi S, Spindler J, Garweg JG. Long-term outcome of intravitreal aflibercept treatment for neovascular age-related macular degeneration using a „treat-and-extend“ regimen. Ophthalmol Retina. 2019;3:393–399. doi:10.1016/j.oret.2019.01.018

 PubMedGoogle Scholar

Richard G, Monés J, Wolf S, et al. Scheduled versus pro re nata dosing in the VIEW trials. Ophthalmology. 2015;122:2497–2503. doi:10.1016/j.ophtha.2015.08.014

 Web of Science ®Google Scholar